수술 중 방사선 치료 시장 : 기술별, 제품 유형별, 시술/수술 접근별, 시술 환경별, 암 유형별, 최종 사용자별 - 세계 예측(2026-2032년)

The Intraoperative Radiation Therapy Market was valued at USD 251.77 million in 2025 and is projected to grow to USD 284.19 million in 2026, with a CAGR of 13.03%, reaching USD 593.67 million by 2032.

Intraoperative radiation therapy represents a convergence of surgical precision and targeted radiotherapeutic delivery, offering a single-encounter treatment paradigm that reduces radiation exposure to surrounding healthy tissue while consolidating care pathways. Over the past decade, advancements in compact radiation delivery systems and refinements in clinical protocols have expanded the range of indications and settings in which IORT can be considered. With ongoing innovation in portable platforms and low-energy devices, IORT is transitioning from highly specialized tertiary centers toward broader adoption across cancer care networks.

Clinical teams increasingly view IORT as a means to streamline perioperative workflows, potentially reducing the need for prolonged external beam radiotherapy in selected patient cohorts. This trend is supported by multidisciplinary collaboration among surgeons, radiation oncologists, medical physicists, and nursing staff, which is essential to integrate IORT into existing surgical and oncologic pathways. Concurrently, device makers have focused on ergonomics, shielding efficiency, and ease of integration to lower procedural complexity and support wider clinical uptake.

Regulatory authorities and professional societies have been refining guidance around patient selection, radiation safety, and training standards to ensure consistent, high-quality implementation. In parallel, health systems are evaluating reimbursement frameworks and care delivery models to balance upfront capital investment with potential operational efficiencies and patient-centric outcomes. Taken together, these dynamics set the stage for strategic decisions by clinical program leaders, device manufacturers, and payers seeking to evaluate the role of IORT within contemporary oncologic care.

Transformative clinical, technological, and care-delivery shifts driving broader consideration and operational integration of intraoperative radiation therapy across health systems

The landscape of intraoperative radiation therapy is undergoing transformative shifts driven by technological miniaturization, procedural standardization, and shifts in care delivery settings. Device innovation has focused on improving dose conformity, reducing shielding requirements, and enabling mobility, which collectively lower barriers to adoption in ambulatory and community hospital environments. As a result, clinical teams can contemplate delivering radiotherapy at the point of tumor resection with greater precision and fewer logistical constraints than in earlier generations of equipment.

Concurrently, evidence synthesis and real-world outcomes reporting have improved clarity around patient selection, enabling more nuanced decisions about which cohorts may derive the most meaningful benefit from a single-session intraoperative approach. These clinical refinements are complemented by evolving training frameworks that emphasize interdisciplinary coordination, safety culture, and reproducible procedural workflows. Because of these developments, institutions that once deferred adoption due to operational complexity are re-evaluating their strategies and piloting IORT programs with cross-functional support.

Financial and policy environments are also shifting, with greater attention to value-based care models and care consolidation. Stakeholders are assessing how IORT might reduce the overall treatment burden for patients by compressing therapy into the operative episode, potentially enhancing patient experience and adherence. Taken together, these forces represent a structural shift in how local control strategies can be integrated into the surgical episode, prompting both providers and manufacturers to adapt commercialization, training, and service models in response.

Assessing how recent tariff and trade dynamics can alter procurement decisions, supply chain resilience, and deployment strategies for intraoperative radiation therapy systems

Tariff policies affecting medical device imports can reverberate across supply chains, procurement strategies, and the economics of deploying advanced intraoperative radiation therapy systems. Increased duties or trade restrictions raise landed costs for imported equipment and components, which in turn can prompt purchasing organizations to re-evaluate acquisition timing, financing arrangements, and vendor selection. When procurement teams anticipate variable import costs, there is often a tendency to prefer suppliers with regional manufacturing footprints or diversified sourcing strategies to mitigate exposure.

Moreover, tariffs can influence the competitive dynamics among device manufacturers. Firms with established domestic production capabilities or localized assembly may be better positioned to maintain stable pricing and competitive lead times, while those reliant on cross-border component flows may absorb costs or pass them on to buyers. In addition to direct price effects, tariffs can affect service and maintenance economics if replacement parts and consumables become subject to additional duties, thereby influencing total cost of ownership considerations for health systems assessing IORT investments.

From a clinical operations perspective, procurement delays or higher equipment costs may slow program rollout timelines, prompting institutions to prioritize phased implementations, shared-service models, or partnerships that spread capital commitments. In turn, these adaptations can change where and how IORT services are offered, with potential implications for access in community settings versus academic centers. Ultimately, trade policy shifts underscore the importance of resilient supply chain planning, transparent cost modeling, and strategic vendor engagement to preserve implementation momentum for intraoperative radiation therapy initiatives.

Key segmentation insights revealing how clinical application, delivery technology, and care setting jointly determine adoption pathways and procedural design choices

Segmentation analysis reveals nuanced drivers of adoption and clinical value across application, technology, and end-user dimensions. Based on Application, the technology is applied across Brain Tumors, Breast Cancer, and Gynecological Cancer, each presenting distinct surgical workflows, dosimetric requirements, and multidisciplinary coordination needs that influence device selection and protocol design. Brain tumor procedures often demand high precision and specialized shielding considerations; breast cancer cases offer opportunities for single-fraction approaches tied to breast conservation strategies; gynecologic malignancies can leverage intraoperative boosts in complex pelvic resections where margin control is critical.

Based on Technology, offerings fall into categories including Electron, Low Energy X Ray, and Portable X Ray, with each modality presenting trade-offs in penetration depth, shielding infrastructure, and operating room integration. Electron-based systems deliver deeper tissue penetration suitable for certain tumor beds but often require more extensive shielding. Low energy X-ray platforms provide surface-weighted dose distributions favorable for select indications and may reduce shielding burdens. Portable X-ray devices prioritize mobility and streamlined workflows, enabling adoption in a wider range of surgical settings but with distinct clinical and dosimetric implications.

Based on End User, typical settings include Ambulatory Surgery Center, Cancer Center, and Hospital, each of which has different capital investment tolerance, staffing models, and patient throughput expectations that shape program feasibility. Ambulatory surgery centers may prioritize compact, low-footprint solutions that minimize capital and operational overhead, while cancer centers and hospitals can invest in more comprehensive infrastructure and multidisciplinary programs. Recognizing these segmentation dimensions helps stakeholders align technology choice, clinical protocols, and service delivery models to institutional capabilities and patient population needs.

Regional dynamics and adoption patterns that influence clinical program development, reimbursement alignment, and distribution strategies across global health markets

Regional perspectives on intraoperative radiation therapy highlight distinct drivers and barriers across major geographies. In the Americas, clinical networks and tertiary centers have been early adopters, supported by robust surgical oncology programs and a focus on consolidating perioperative care; however, variations in reimbursement practices and capital cycles influence where programs scale beyond major metropolitan centers. Transitional initiatives in community hospitals and selected ambulatory settings are increasingly visible as institutions seek to enhance local access to advanced oncologic therapies.

In Europe, Middle East & Africa, heterogeneous healthcare systems produce a mosaic of adoption patterns. High-resource centers in Western Europe have integrated IORT into specialized pathways, while some regions prioritize centralized delivery in referral institutions to concentrate expertise and manage resource utilization. Regulatory harmonization efforts and cross-border clinical collaborations play a role in knowledge dissemination and training, enabling centers of excellence to catalyze broader regional capability building.

In Asia-Pacific, rapid growth of surgical oncology services, investments in cancer infrastructure, and interest in portable and low-footprint devices are driving exploratory programs across both urban and peri-urban hospitals. Diverse payer models and evolving clinical guidelines shape adoption, and partnerships between local distributors and technology providers often determine the feasibility of expanding access. Across all regions, workforce training, radiation safety infrastructure, and alignment of clinical pathways remain central to sustainable program development.

Strategic competitive positioning and service-driven differentiators shaping supplier selection, clinical adoption, and long-term program sustainability in intraoperative radiation therapy

The competitive environment for intraoperative radiation therapy comprises established medical device firms, specialist radiation companies, and emerging entrants focused on novel delivery platforms and services. Players are differentiating through technological advancements such as compact generators, optimized applicators, and integrated imaging or navigation aids that enhance targeting and procedural efficiency. Strategic priorities include reducing shielding burdens, shortening setup times, and enabling seamless integration into the surgical workflow to lower operational friction and improve throughput.

Partnerships and service models are increasingly central to commercial strategies. Suppliers are offering bundled solutions that combine equipment with training programs, clinical support, and maintenance services to help healthcare providers achieve predictable implementation outcomes. Additionally, clinical evidence generation and post-market registries are becoming important competitive levers; firms that can demonstrate reproducible outcomes, procedural efficiency, and safety across diverse practice settings gain credibility with institutional purchasers and clinical champions.

Investment in after-sales support and regional service networks also affects adoption, particularly where uptime and rapid technical response are critical to surgical scheduling. As a result, companies that align product design with practical clinical workflows and offer robust education and service infrastructure are better positioned to influence program design decisions and long-term purchasing relationships.

Actionable recommendations for healthcare executives and clinical leaders to implement intraoperative radiation therapy programs with operational rigor and measurable outcomes

Leaders considering IORT adoption should prioritize actionable steps that align clinical value with operational feasibility. First, establish multidisciplinary governance that includes surgical, radiation oncology, medical physics, nursing, and administrative stakeholders to create reproducible protocols, define safety checklists, and manage training pathways. Early engagement across these groups accelerates consensus on patient selection criteria and procedural responsibilities, reducing implementation risk and ensuring consistent quality of care.

Second, evaluate procurement options that balance device capabilities with institutional workflow constraints. Consider total lifecycle implications including consumables, service contracts, and supply chain resilience. Where trade policy or sourcing risks exist, prioritize vendors with local assembly or diversified supply chains to preserve operational continuity. Pilot programs with phased scale-up can validate clinical and economic assumptions while providing necessary data to refine protocols.

Third, invest in outcome measurement and knowledge dissemination by establishing registries or participating in collaborative data initiatives. Transparent reporting on clinical outcomes, complication rates, and patient experience supports internal decision-making and external stakeholder confidence. Finally, align reimbursement and financial planning with clinical objectives by engaging payers early to articulate the potential patient-centric benefits and to explore case-based or bundled payment approaches that reflect the procedural consolidation enabled by intraoperative radiotherapy.

Transparent research methodology combining primary expert interviews, secondary clinical and regulatory analysis, and triangulated validation to ensure actionable and reliable insights

The research approach underpinning this analysis blended qualitative and quantitative techniques to produce a comprehensive view of intraoperative radiation therapy adoption, supply dynamics, and clinical practice patterns. Primary research included interviews with surgical oncologists, radiation oncologists, medical physicists, procurement leads, and device specialists to capture frontline operational insights and to identify barriers and enablers observed in real-world implementations. Secondary analysis comprised peer-reviewed clinical literature, regulatory documentation, health system reports, and publicly available technical specifications to corroborate clinical and technical assertions.

Triangulation methods were applied to reconcile differing perspectives and to ensure findings reflect both clinical evidence and operational realities. This included cross-referencing interview findings with device specifications and training frameworks, and validating regional adoption narratives against institutional case studies. In addition, scenario analysis was used to explore how supply chain disruptions, policy changes, or technological shifts could influence procurement and deployment choices, with an emphasis on practical implications rather than numerical forecasting.

Finally, quality controls included expert review of draft findings by clinicians and health system administrators to ensure accuracy, relevance, and applicability. The resulting synthesis emphasizes actionable insights, readiness considerations, and strategic options designed to support decision-making for clinical program leaders and commercial stakeholders.

Concluding synthesis on how technological progress and operational readiness together determine the sustainable integration of intraoperative radiation therapy within oncologic care pathways

Intraoperative radiation therapy stands at an inflection point where technological maturity, clinical evidence, and service model innovation converge to offer new pathways for perioperative oncologic care. Devices that reduce operational complexity and shielding requirements, coupled with standardized training and multidisciplinary governance, create realistic pathways for expanded adoption beyond early adopter institutions. This evolution promises improved integration of local control strategies into single-encounter surgical care while also demanding careful attention to implementation logistics and long-term service commitments.

As care delivery and procurement landscapes evolve, stakeholders should approach IORT adoption with a balanced view that weighs clinical potential against operational, regulatory, and supply chain realities. Effective programs will be those that plan comprehensively: defining clinical indications clearly, investing in multidisciplinary training, ensuring device selection aligns with institutional workflows, and establishing mechanisms for outcome measurement and continual improvement. When these elements are combined, IORT can become a reliable component of contemporary oncologic practice, improving the patient experience while fitting into broader strategic objectives for surgical and radiation oncology services.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Intraoperative Radiation Therapy Market, by Technology

• 8.1. Electron
• 8.2. Low Energy X Ray
• 8.3. Portable X Ray

9. Intraoperative Radiation Therapy Market, by Product Type

• 9.1. IORT Equipment / Radiation Systems
  • 9.1.1. Mobile electron accelerators
  • 9.1.2. Miniaturized X-ray IORT systems
• 9.2. Applicators & Accessories
  • 9.2.1. Spherical applicators
  • 9.2.2. Flat applicators

10. Intraoperative Radiation Therapy Market, by Procedure / Surgical Approach

• 10.1. Breast-Conserving Surgery (BCS)
• 10.2. Tumor Bed Boost During Cancer Surgery
• 10.3. Debulking Surgery + Radiation Boost

11. Intraoperative Radiation Therapy Market, by Procedure Setting

• 11.1. Inpatient Surgical Procedures
• 11.2. Outpatient / Day-Care Procedures

12. Intraoperative Radiation Therapy Market, by Cancer Application

• 12.1. Brain Tumors
• 12.2. Breast Cancer
• 12.3. Gynecological Cancer

13. Intraoperative Radiation Therapy Market, by End User

• 13.1. Ambulatory Surgery Center
• 13.2. Cancer Center
• 13.3. Hospital

14. Intraoperative Radiation Therapy Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Intraoperative Radiation Therapy Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Intraoperative Radiation Therapy Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. United States Intraoperative Radiation Therapy Market

18. China Intraoperative Radiation Therapy Market

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025
• 19.5. Accuray Incorporated
• 19.6. Aries Medical Systems Ltd.
• 19.7. Brainlab AG
• 19.8. Carl Zeiss Meditec AG
• 19.9. Eckert & Ziegler Radiopharma
• 19.10. Elekta AB
• 19.11. GMV Innovating Solutions
• 19.12. iCAD, Inc.
• 19.13. InfoMedics AG
• 19.14. IntraOp Medical, Inc.
• 19.15. Ion Beam Applications SA
• 19.16. Isoray, Inc.
• 19.17. Panacea Medical Technologies Pvt. Ltd.
• 19.18. Salutaris Medical Devices
• 19.19. Sensus Healthcare, Inc.
• 19.20. Sordina IORT Technologies
• 19.21. Varian Medical Systems, Inc.